Scottish review of Pegvisomant - patient responses needed
The Pituitary Foundation are participating in the current appraisal review of the medicine Pegvisomant in Scotland.
Pegvisomant (Somavert®) is used for the treatment of patients with Acromegaly who have had an inadequate response to surgery and/or radiation therapy and other medical treatment did not normalize IGF-I concentrations or was not tolerated.
The Pituitary Foundation is participating in The Scottish Medicines Consortium review of Pegvisomant, representing the patient/carer perspective and we would very much appreciate your important input.
We would like to hear from you if you live anywhere in the UK (but particularly Scotland) and are:
a) an Acromegaly patient and you take Pegvisomant
b) an Acromegaly patient who is eligible for Pegvisomant, but your local health authority will not fund the medicine
c) a carer of either a) or b).
We have a simple questionnaire which it would be very useful if you had time to complete, please email email@example.com to be sent a copy of the questionnaire. Alternatively please do contact Rosa by telephone on 0117 370 1316 to talk with her over the phone about your experience. If you are unable to fill in the form yourself she can do this for you during the telephone conversation.
We do not have very long to collect patient responses so if you can please respond by the end of the day Wednesday August 2nd that would be much appreciated (We are sorry but any late responses cannot be included).
Thank you very much for your help with this.